Your selection

Innovation / 03.03.2023
Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.

Eckert & Ziegler (ISIN DE0005659700, SDAX) has successfully submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration for lutetium (177Lu) chloride solution (containing no-carrier-added radioisotope Lutetium-177), an active pharmaceutical ingredient and received DMF registration number 038043.

Drug manufacturers can now refer to this DMF when developing new radiopharmaceuticals for the U.S. market and use the lutetium (177Lu) chloride solution in clinical trials of drugs, for example. A large number of tumor-specific drugs can be labeled with the beta emitter lutetium-177, which brings the radiating effect of the isotope directly to the tumor cell.

"We are excited about the access to the U.S. market for lutetium-177 based radiotherapeutics," explains Dr. Lutz Helmke, member of the Executive Board and responsible for the Medical segment at Eckert & Ziegler. "Thanks to our joint venture with Atom Mines LLC, we have excellent access to the scarce and indispensable precursor ytterbium-176 and thus the possibility to supply no-carrier-added lutetium-177 in highest purity and reliably to pharmaceutical customers worldwide."

Radionuclide therapy with lutetium-177, is becoming well established as a valuable treatment option within precision oncology for various indications. Eckert & Ziegler is one of the leading partners for the radiopharmaceutical industry, offering complete early development services in addition to the supply of isotopes, including process development and scale-up, CMC development, manufacturing and packaging, product release and stability programs.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with nearly 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

www.ezag.com

Overview News

News Buch Berlin

The Imaging Innovation Center hits a milestone

The Max Delbrück Center, Berlin, celebrates its new, innovative research building with a “topping-out ceremony.” The Imaging Innovation Center, designed by the architectural firm heinlewischer, will h...

more ...

Giant with a Ceramic Heart

A new NMR spectrometer has been in operation at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) since the end of May.

more ...

Holger Gerhardt new member of the DZHK Board of Directors

Professor Holger Gerhardt from the DZHK partner site Berlin was newly elected to the Board of Directors by the General Assembly: He will take office on 1 July 2024.

more ...

Events Buch Berlin

17.08.2024, 21:15
Open Air Sommerkino in Hobrechtsfelde: "Dirty Dancing"

Kultfilm von 1987

more ...

10.09.2024, 09:00
From Target to Market - The GLA Biotech & Pharma Summer School

The 4-day intensive course provides a comprehensive overview of the entire drug development process in biotechnology and in the pharmaceutical industry – from the idea to the market.

more ...

12.09.2024, 09:00
Realtime PCR und digital PCR Kurs

Der RealTime PCR und Digital PCR Kurs richtet sich an erfahrene PCR Anwender*innen und an Einsteiger*innen. Wichtige PCR Grundlagen werden erörtert, bevor die RealTime PCR besprochen und Genexpression...

more ...

This website is supported by: